Formation and propagation of tau oligomeric seeds

Frontiers in Neurology

Volumn 4 JUL, Issue , 2013, Pages

  Gerson, Julia E ^a   Kayed, Rakez ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Alzheimer's; Oligomeric seeding; Propagation of tau pathology; Tau oligomers; Tauopathies

Indexed keywords

ALKALINE PHOSPHATASE; ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; BUNGAROTOXIN RECEPTOR; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MITOGEN ACTIVATED PROTEIN KINASE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OLIGOMER; PRION PROTEIN; PROTEIN KINASE FYN; RAB PROTEIN; RAS PROTEIN; TAU PROTEIN;

ALZHEIMER DISEASE; CELL STRESS; CHANNEL GATING; ENDOCYTOSIS; EXOCYTOSIS; EXOSOME; FRONTOTEMPORAL DEMENTIA; HUMAN; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; REVIEW; TAUOPATHY;

EID: 84883502695     PISSN: None     EISSN: 16642295     Source Type: Journal    
DOI: 10.3389/fneur.2013.00093     Document Type: Review

References (138)

1. Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci (2007) 8:663-72.
2. Gendron TF, Petrucelli L. The role of tau in neurodegeneration. Mol Neurodegener (2009) 4:13. doi:10.1186/1750-1326-4-13
3. Gomez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol (1997) 41:17-24. doi:10.1002/ana.410410106
4. Morsch R, Simon W, Coleman PD. Neurons may live for decades with neurofibrillary tangles. J Neuropathol Exp Neurol (1999) 58:188-97. doi:10.1097/00005072-199902000-00008
5. Kril JJ, Patel S, Harding AJ, Halliday GM. Neuron loss from the hippocampus of Alzheimer's disease exceeds extracellular neurofibrillary tangle formation. Acta Neuropathol (2002) 103:370-6. doi:10.1007/s00401-001-0477-5
6. Haroutunian V, Davies P, Vianna C, Buxbaum JD, Purohit DP. Tau protein abnormalities associated with the progression of Alzheimer disease type dementia. Neurobiol Aging (2007) 28:1-7. doi:10.1016/j.neurobiolaging.2005.11.001
7. Spires TL, Orne JD, Santacruz K, Pitstick R, Carlson GA, Ashe KH, et al. Region-specific dissociation of neuronal loss and neurofibrillary pathology in a mouse model of tauopathy. Am J Pathol (2006) 168:1598-607. doi:10.2353/ajpath.2006.050840
8. Berger Z, Roder H, Hanna A, Carlson A, Rangachari V, Yue M, et al. Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J Neurosci (2007) 27:3650-62. doi:10.1523/JNEUROSCI.0587-07.2007
9. Maeda S, Sahara N, Saito Y, Murayama M, Yoshiike Y, Kim H, et al. Granular tau oligomers as intermediates of tau filaments. Biochemistry (2007) 46:3856-61. doi:10.1021/bi061359o
10. Kopeikina KJ, Carlson GA, Pitstick R, Ludvigson AE, Peters A, Luebke JI, et al. Tau accumulation causes mitochondrial distribution deficits in neurons in a mouse model of tauopathy and in human Alzheimer's disease brain. Am J Pathol (2011) 179:2071-82. doi:10.1016/j.ajpath.2011.07.004
11. Cowan CM, Quraishe S, Mudher A. What is the pathological significance of tau oligomers?. Biochem Soc Trans (2012) 40:693-7. doi:10.1042/BST20120135
12. Sahara N, Deture M, Ren Y, Ebrahim AS, Kang D, Knight J, et al. Characteristics of TBS-extractable hyperphosphorylated tau species: aggregation intermediates in rTg4510 mouse brain. J Alzheimers Dis (2013) 33:249-63.
13. Andorfer C, Kress Y, Espinoza M, De Silva R, Tucker KL, Barde YA, et al. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem (2003) 86:582-90. doi:10.1046/j.1471-4159.2003.01879.x
14. Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron (2007) 53:337-51. doi:10.1016/j.neuron.2007.01.010
15. Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science (2005) 309:476-81. doi:10.1126/science.1113694
16. de Calignon A, Fox LM, Pitstick R, Carlson GA, Bacskai BJ, Spires-Jones TL, et al. Caspase activation precedes and leads to tangles. Nature (2010) 464:1201-4. doi:10.1038/nature08890
17. Sydow A, Van Der Jeugd A, Zheng F, Ahmed T, Balschun D, Petrova O, et al. Tau-induced defects in synaptic plasticity, learning, and memory are reversible in transgenic mice after switching off the toxic Tau mutant. J Neurosci (2011) 31:2511-25. doi:10.1523/JNEUROSCI.5245-10.2011
18. Wittmann CW, Wszolek MF, Shulman JM, Salvaterra PM, Lewis J, Hutton M, et al. Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science (2001) 293:711-4. doi:10.1126/science.1062382
19. Cowan CM, Bossing T, Page A, Shepherd D, Mudher A. Soluble hyper-phosphorylated tau causes microtubule breakdown and functionally compromises normal tau in vivo. Acta Neuropathol (2010) 120:593-604. doi:10.1007/s00401-010-0716-8
20. Ali YO, Ruan K, Zhai RG. NMNAT suppresses tau-induced neurodegeneration by promoting clearance of hyperphosphorylated tau oligomers in a Drosophila model of tauopathy. Hum Mol Genet (2012) 21:237-50. doi:10.1093/hmg/ddr449
21. Maeda S, Sahara N, Saito Y, Murayama S, Ikai A, Takashima A. Increased levels of granular tau oligomers: an early sign of brain aging and Alzheimer's disease. Neurosci Res (2006) 54:197-201. doi:10.1016/j.neures.2005.11.009
22. Patterson KR, Remmers C, Fu Y, Brooker S, Kanaan NM, Vana L, et al. Characterization of prefibrillar tau oligomers in vitro and in Alzheimer's disease. J Biol Chem (2011) 286:23063-76. doi:10.1074/jbc.M111.237974
23. Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Sarmiento J, Troncoso J, Jackson GR, et al. Identification of oligomers at early stages of tau aggregation in Alzheimer's disease. FASEB J (2012) 26:1946-59. doi:10.1096/fj.11-199851
24. Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Clos AL, Jackson GR, Kayed R. Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice. Mol Neurodegener (2011) 6:39. doi:10.1186/1750-1326-6-39
25. Walker LC, Diamond MI, Duff KE, Hyman BT. Mechanisms of protein seeding in neurodegenerative diseases. JAMA Neurol (2013) 70:304-10. doi:10.1001/jamaneurol.2013.1453
26. Serio TR, Cashikar AG, Kowal AS, Sawicki GJ, Moslehi JJ, Serpell L, et al. Nucleated conformational conversion and the replication of conformational information by a prion determinant. Science (2000) 289:1317-21. doi:10.1126/science.289.5483.1317
27. Lee J, Culyba EK, Powers ET, Kelly JW. Amyloid-beta forms fibrils by nucleated conformational conversion of oligomers. Nat Chem Biol (2011) 7:602-9. doi:10.1038/nchembio.624
28. Margittai M, Langen R. Template-assisted filament growth by parallel stacking of tau. Proc Natl Acad Sci U S A (2004) 101:10278-83. doi:10.1073/pnas.0401911101
29. Wille H, Drewes G, Biernat J, Mandelkow EM, Mandelkow E. Alzheimer-like paired helical filaments and antiparallel dimers formed from microtubule-associated protein tau in vitro. J Cell Biol (1992) 118:573-84. doi:10.1083/jcb.118.3.573
30. Chang E, Kim S, Yin H, Nagaraja HN, Kuret J. Pathogenic missense MAPT mutations differentially modulate tau aggregation propensity at nucleation and extension steps. J Neurochem (2008) 107:1113-23.
31. Congdon EE, Kim S, Bonchak J, Songrug T, Matzavinos A, Kuret J. Nucleation-dependent tau filament formation: the importance of dimerization and an estimation of elementary rate constants. J Biol Chem (2008) 283:13806-16. doi:10.1074/jbc.M800247200
32. King ME, Ahuja V, Binder LI, Kuret J. Ligand-dependent tau filament formation: implications for Alzheimer's disease progression. Biochemistry (1999) 38:14851-9. doi:10.1021/bi9911839
33. von Bergen M, Barghorn S, Biernat J, Mandelkow E-M, Mandelkow E. Tau aggregation is driven by a transition from random coil to beta sheet structure. Biochim Biophys Acta (2005) 1739:158-66. doi:10.1016/j.bbadis.2004.09.010
34. Wilson DM, Binder LI. Free fatty acids stimulate the polymerization of tau and amyloid beta peptides. In vitro evidence for a common effector of pathogenesis in Alzheimer's disease. Am J Pathol (1997) 150:2181-95.
35. King ME, Gamblin TC, Kuret J, Binder LI. Differential assembly of human tau isoforms in the presence of arachidonic acid. J Neurochem (2000) 74:1749-57. doi:10.1046/j.1471-4159.2000.0741749.x
36. Barghorn S, Mandelkow E. Toward a unified scheme for the aggregation of tau into Alzheimer paired helical filaments. Biochemistry (2002) 41:14885-96.
37. Chirita CN, Necula M, Kuret J. Anionic micelles and vesicles induce tau fibrillization in vitro. J Biol Chem (2003) 278:25644-50. doi:10.1074/jbc.M301663200
38. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A (1986) 83:4913-7. doi:10.1073/pnas.83.13.4913
39. Lee VMY, Balin BJ, Otvos L Jr., Trojanowski JQ. A68: a major subunit of paired helical filaments and derivatized forms of normal tau. Science (1991) 251:675-8. doi:10.1126/science.1899488
40. Pérez M, Cuadros R, Smith MA, Perry G, Avila J. Phosphorylated, but not native, tau protein assembles following reaction with the lipid peroxidation product, 4-hydroxy-2-nonenal. FEBS Lett (2000) 486:270-4. doi:10.1016/S0014-5793(00)02323-1
41. Alonso ADC, Zaidi T, Novak M, Barra HS, Grundke-Iqbal I, Iqbal K. Interaction of tau isoforms with Alzheimer's disease abnormally hyperphosphorylated tau and in vitro phosphorylation into the disease-like protein. J Biol Chem (2001) 276:37967-73.
42. Alonso ADC, Zaidi T, Novak M, Grundke-Iqbal I, Iqbal K. Hyperphosphorylation induces self-assembly of τ into tangles of paired helical filaments/straight filaments. Proc Natl Acad Sci U S A (2001) 98:6923-8. doi:10.1073/pnas.121119298
43. Biernat J, Gustke N, Drewes G, Mandelkow E, Mandelkow E. Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubule binding. Neuron (1993) 11:153-63. doi:10.1016/0896-6273(93)90279-Z
44. Bramblett GT, Goedert M, Jakes R, Merrick SE, Trojanowski JQ, Lee VMY. Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding. Neuron (1993) 10:1089-99. doi:10.1016/0896-6273(93)90057-X
45. Sengupta A, Kabat J, Novak M, Wu Q, Grundke-Iqbal I, Iqbal K. Phosphorylation of tau at both Thr 231 and Ser 262 is required for maximal inhibition of its binding to microtubules. Arch Biochem Biophys (1998) 357:299-309. doi:10.1006/abbi.1998.0813
46. Hasegawa M, Smith MJ, Goedert M. Tau proteins with FTDP-17 mutations have a reduced ability to promote microtubule assembly. FEBS Lett (1998) 437:207-10. doi:10.1016/S0014-5793(98)01217-4
47. Barghorn S, Zheng-Fischhöfer Q, Ackmann M, Biernat J, Von Bergen M, Mandelkow EM, et al. Structure, microtubule interactions, and paired helical filament aggregation by tau mutants of frontotemporal dementias. Biochemistry (2000) 39:11714-21.
48. DeTure M, Ko L-W, Yen S, Nacharaju P, Easson C, Lewis J, et al. Missense tau mutations identified in FTDP-17 have a small effect on tau-microtubule interactions. Brain Res (2000) 853:5-14. doi:10.1016/S0006-8993(99)02124-1
49. Poorkaj P, Muma NA, Zhukareva V, Cochran EJ, Shannon KM, Hurtig H, et al. An R5L τ mutation in a subject with a progressive supranuclear palsy phenotype. Ann Neurol (2002) 52:511-6. doi:10.1002/ana.10340
50. Harada M, Isersky C, Cuatrecasas P, Page D, Bladen HA, Eanes ED, et al. Human amyloid protein: chemical variability and homogeneity. J Histochem Cytochem (1971) 19:1-15.
51. von Bergen M, Barghorn S, Li L, Marx A, Biernat J, Mandelkow E-M, et al. Mutations of tau protein in frontotemporal dementia promote aggregation of paired helical filaments by enhancing local β-structure. J Biol Chem (2001) 276:48165-74.
52. Friedhoff P, Schneider A, Mandelkow E-M, Mandelkow E. Rapid assembly of Alzheimer-like paired helical filaments from microtubule-associated protein tau monitored by fluorescence in solution. Biochemistry (1998) 37:10223-30. doi:10.1021/bi980537d
53. Lira-De León KI, García-Gutiérrez P, Serratos IN, Palomera-Cárdenas M, Figueroa-Corona MDP, Campos-Peña V, et al. Molecular mechanism of tau aggregation induced by anionic and cationic dyes. J Alzheimers Dis (2013) 35:319-34. doi:10.3233/JAD-121765
54. Kim Y-S, Randolph TW, Manning MC, Stevens FJ, Carpenter JF. Congo red populates partially unfolded states of an amyloidogenic protein to enhance aggregation and amyloid fibril formation. J Biol Chem (2003) 278:10842-50. doi:10.1074/jbc.M212540200
55. Congdon EE, Necula M, Blackstone RD, Kuret J. Potency of a tau fibrillization inhibitor is influenced by its aggregation state. Arch Biochem Biophys (2007) 465:127-35. doi:10.1016/j.abb.2007.05.004
56. Silveira JR, Raymond GJ, Hughson AG, Race RE, Sim VL, Hayes SF, et al. The most infectious prion protein particles. Nature (2005) 437:257-61. doi:10.1038/nature03989
57. Langer F, Eisele YS, Fritschi SK, Staufenbiel M, Walker LC, Jucker M. Soluble Abeta seeds are potent inducers of cerebral beta-amyloid deposition. J Neurosci (2011) 31:14488-95. doi:10.1523/JNEUROSCI.3088-11.2011
58. Ruschak AM, Miranker AD. The role of prefibrillar structures in the assembly of a peptide amyloid. J Mol Biol (2009) 393:214-26. doi:10.1016/j.jmb.2009.06.026
59. Lasagna-Reeves CA, Castillo-Carranza DL, Guerrero-Muoz MJ, Jackson GR, Kayed R. Preparation and characterization of neurotoxic tau oligomers. Biochemistry (2010) 49:10039-41. doi:10.1021/bi1016233
60. Mandelkow EM, Biernat J, Drewes G, Steiner B, Lichtenberg-Kraag B, Wille H, et al. Microtubule-associated protein tau, paired helical filaments, and phosphorylation. Ann N Y Acad Sci (1993) 695:209-16. doi:10.1111/j.1749-6632.1993.tb23054.x
61. Ahmad A, Uversky VN, Hong D, Fink AL. Early events in the fibrillation of monomeric insulin. J Biol Chem (2005) 280:42669-75. doi:10.1074/jbc.M504298200
62. Bernstein SL, Dupuis NF, Lazo ND, Wyttenbach T, Condron MM, Bitan G, et al. Amyloid-beta protein oligomerization and the importance of tetramers and dodecamers in the aetiology of Alzheimer's disease. Nat Chem (2009) 1:326-31. doi:10.1038/nchem.247
63. Frare E, Mossuto MF, De Laureto PP, Tolin S, Menzer L, Dumoulin M, et al. Characterization of oligomeric species on the aggregation pathway of human lysozyme. J Mol Biol (2009) 387:17-27. doi:10.1016/j.jmb.2009.01.049
64. Chirita CN, Congdon EE, Yin H, Kuret J. Triggers of full-length tau aggregation: a role for partially folded intermediates. Biochemistry (2005) 44:5862-72. doi:10.1021/bi0500123
65. Littauer UZ, Giveon D, Thierauf M, Ginzburg I, Ponstingl H. Common and distinct tubulin binding sites for microtubule-associated proteins. Proc Natl Acad Sci U S A (1986) 83:7162-6. doi:10.1073/pnas.83.19.7162
66. Kampers T, Friedhoff P, Biernat J, Mandelkow EM, Mandelkow E. RNA stimulates aggregation of microtubule-associated protein tau into Alzheimer-like paired helical filaments. FEBS Lett (1996) 399:344-9. doi:10.1016/S0014-5793(96)01386-5
67. Giasson BI, Forman MS, Higuchi M, Golbe LI, Graves CL, Kotzbauer PT, et al. Initiation and synergistic fibrillization of tau and alpha-synuclein. Science (2003) 300:636-40. doi:10.1126/science.1082324
68. Sahara N, Maeda S, Murayama M, Suzuki T, Dohmae N, Yen S-H, et al. Assembly of two distinct dimers and higher-order oligomers from full-length tau. Eur J Neurosci (2007) 25:3020-9. doi:10.1111/j.1460-9568.2007.05555.x
69. Matthes D, Gapsys V, De Groot BL. Driving forces and structural determinants of steric zipper peptide oligomer formation elucidated by atomistic simulations. J Mol Biol (2012) 421:390-416. doi:10.1016/j.jmb.2012.02.004
70. Wang YP, Biernat J, Pickhardt M, Mandelkow E, Mandelkow E-M. Stepwise proteolysis liberates tau fragments that nucleate the Alzheimer-like aggregation of full-length tau in a neuronal cell model. Proc Natl Acad Sci U S A (2007) 104:10252-7. doi:10.1073/pnas.0703676104
71. Kfoury N, Holmes BB, Jiang H, Holtzman DM, Diamond MI. Trans-cellular propagation of tau aggregation by fibrillar species. J Biol Chem (2012) 287:19440-51. doi:10.1074/jbc.M112.346072
72. Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Guerrero-Munoz MJ, Kiritoshi T, Neugebauer V, et al. Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Sci Rep (2012) 2:700. doi:10.1038/srep00700
73. Busciglio J, Lorenzo A, Yeh J, Yankner BA. Beta-amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron (1995) 14:879-88. doi:10.1016/0896-6273(95)90232-5
74. Gotz J, Chen F, Van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science (2001) 293:1491-5. doi:10.1126/science.1062097
75. Ferrari A, Hoerndli F, Baechi T, Nitsch RM, Gotz J. Beta-amyloid induces paired helical filament-like tau filaments in tissue culture. J Biol Chem (2003) 278:40162-8. doi:10.1074/jbc.M308243200
76. Waxman EA, Giasson BI. Induction of intracellular tau aggregation is promoted by α-synuclein seeds and provides novel insights into the hyperphosphorylation of tau. J Neurosci (2011) 31:7604-18. doi:10.1523/JNEUROSCI.0297-11.2011
77. Ono K, Takahashi R, Ikeda T, Yamada M. Cross-seeding effects of amyloid β-protein and α-synuclein. J Neurochem (2012) 122:883-90. doi:10.1111/j.1471-4159
78. Walker LC, Callahan MJ, Bian F, Durham RA, Roher AE, Lipinski WJ. Exogenous induction of cerebral β-amyloidosis in βAPP-transgenic mice. Peptides (2002) 23:1241-7. doi:10.1016/S0196-9781(02)00059-1
79. Meyer-Luehmann M, Coomaraswamy J, Bolmont T, Kaeser S, Schaefer C, Kilger E, et al. Exogenous induction of cerebral β-amyloidogenesis is governed by agent and host. Science (2006) 313:1781-4. doi:10.1126/science.1131864
80. Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, Probst A, et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol (2009) 11:909-13. doi:10.1038/ncb1901
81. de Calignon A, Polydoro M, Suarez-Calvet M, William C, Adamowicz DH, Kopeikina KJ, et al. Propagation of tau pathology in a model of early Alzheimer's disease. Neuron (2012) 73:685-97. doi:10.1016/j.neuron.2011.11.033
82. Liu L, Drouet V, Wu JW, Witter MP, Small SA, Clelland C, et al. Trans-synaptic spread of tau pathology in vivo. PLoS ONE (2012) 7:e31302. doi:10.1371/journal.pone.0031302
83. Wu JW, Herman M, Liu L, Simoes S, Acker CM, Figueroa H, et al. Small misfolded tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons. J Biol Chem (2013) 288:1856-70. doi:10.1074/jbc.M112.394528
84. Frost B, Jacks RL, Diamond MI. Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem (2009) 284:12845-52. doi:10.1074/jbc.M808759200
85. Guo JL, Lee VM-Y. Seeding of normal tau by pathological tau conformers drives pathogenesis of Alzheimer-like tangles. J Biol Chem (2011) 286:15317-31. doi:10.1074/jbc.M110.209296
86. Frost B, Ollesch J, Wille H, Diamond MI. Conformational diversity of wild-type tau fibrils specified by templated conformation change. J Biol Chem (2009) 284:3546-51. doi:10.1074/jbc.M805627200
87. Dotti CG, Banker GA, Binder LI. The expression and distribution of the microtubule-associated proteins tau and microtubule-associated protein 2 in hippocampal neurons in the rat in situ and in cell culture. Neuroscience (1987) 23:121-30. doi:10.1016/0306-4522(87)90276-4
88. Lee G, Newman ST, Gard DL, Band H, Panchamoorthy G. Tau interacts with src-family non-receptor tyrosine kinases. J Cell Sci (1998) 111:3167-77.
89. Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, Van Eersel J, et al. Dendritic function of tau mediates amyloid-β toxicity in Alzheimer's disease mouse models. Cell (2010) 142:387-97. doi:10.1016/j.cell.2010.06.036
90. Avila J, Lucas JJ, Perez M, Hernandez F. Role of tau protein in both physiological and pathological conditions. Physiol Rev (2004) 84:361-84.
91. Lee S, Kim W, Li Z, Hall GF. Accumulation of vesicle-associated human tau in distal dendrites drives degeneration and tau secretion in an in situ cellular tauopathy model. Int J Alzheimers Dis (2012) 2012:1-16. doi:10.1155/2012/172837
92. Tai H-C, Serrano-Pozo A, Hashimoto T, Frosch MP, Spires-Jones TL, Hyman BT. The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system. Am J Pathol (2012) 181:1426-35. doi:10.1016/j.ajpath.2012.06.033
93. Díaz-Hernández M, Gómez-Ramos A, Rubio A, Gómez-Villafuertes R, Naranjo JR, Miras-Portugal MT, et al. Tissue-nonspecific alkaline phosphatase promotes the neurotoxicity effect of extracellular tau. J Biol Chem (2010) 285:32539-48. doi:10.1074/jbc.M110.145003
94. Pooler AM, Phillips EC, Lau DHW, Noble W, Hanger DP. Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Rep (2013) 14:389-94. doi:10.1038/embor.2013.15
95. Plouffe V, Mohamed N-V, Rivest-Mcgraw J, Bertrand J, Lauzon M, Leclerc N. Hyperphosphorylation and cleavage at D421 enhance tau secretion. PLoS ONE (2012) 7:e36873. doi:10.1371/journal.pone.0036873
96. Li Y, Liu L, Barger SW, Griffin WST. Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. J Neurosci (2003) 23:1605-11.
97. Bhaskar K, Konerth M, Kokiko-Cochran ON, Cardona A, Ransohoff RM, Lamb BT. Regulation of tau pathology by the microglial fractalkine receptor. Neuron (2010) 68:19-31. doi:10.1016/j.neuron.2010.08.023
98. Ghosh S, Wu MD, Shaftel SS, Kyrkanides S, Laferla FM, Olschowka JA, et al. Sustained interleukin-1 overexpression exacerbates tau pathology despite reduced amyloid burden in an Alzheimer's mouse model. J Neurosci (2013) 33:5053-64. doi:10.1523/JNEUROSCI.4361-12.2013
99. Nash KR, Lee DC, Hunt JB Jr., Morganti JM, Selenica M-L, Moran P, et al. Fractalkine overexpression suppresses tau pathology in a mouse model of tauopathy. Neurobiol Aging (2013) 34:1540-8. doi:10.1016/j.neurobiolaging.2012.12.011
100. Sultan A, Nesslany F, Violet M, Bégard S, Loyens A, Talahari S, et al. Nuclear tau, a key player in neuronal DNA protection. J Biol Chem (2011) 286:4566-75. doi:10.1074/jbc.M110.199976
101. Coppede F, Migliore L. DNA damage and repair in Alzheimer's disease. Curr Alzheimer Res (2009) 6:36-47. doi:10.2174/156720509787313970
102. Arrasate M, Pérez M, Avila J. Tau dephosphorylation at tau-1 site correlates with its association to cell membrane. Neurochem Res (2000) 25:43-50. doi:10.1023/A:1007583214722
103. Pooler AM, Usardi A, Evans CJ, Philpott KL, Noble W, Hanger DP. Dynamic association of tau with neuronal membranes is regulated by phosphorylation. Neurobiol Aging (2012) 33:431.e427-38. doi:10.1016/j.neurobiolaging.2011.01.005
104. Kanu N, Imokawa Y, Drechsel DN, Williamson RA, Birkett CR, Bostock CJ, et al. Transfer of scrapie prion infectivity by cell contact in culture. Curr Biol (2002) 12:523-30. doi:10.1016/S0960-9822(02)00722-4
105. Yang W, Dunlap JR, Andrews RB, Wetzel R. Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells. Hum Mol Genet (2002) 11:2905-17. doi:10.1093/hmg/11.23.2905
106. Magalhães AC, Baron GS, Lee KS, Steele-Mortimer O, Dorward D, Prado MAM, et al. Uptake and neuritic transport of scrapie prion protein coincident with infection of neuronal cells. J Neurosci (2005) 25:5207-16. doi:10.1523/JNEUROSCI.0653-05.2005
107. Ren PH, Lauckner JE, Kachirskaia I, Heuser JE, Melki R, Kopito RR. Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates. Nat Cell Biol (2009) 11:219-25. doi:10.1038/ncb1830
108. Lasagna-Reeves CA, Glabe CG, Kayed R. Amyloid-β annular protofibrils evade fibrillar fate in Alzheimer disease brain. J Biol Chem (2011) 286:22122-30. doi:10.1074/jbc.M111.236257
109. Kayed R, Sokolov Y, Edmonds B, Mcintire TM, Milton SC, Hall JE, et al. Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J Biol Chem (2004) 279:46363-6. doi:10.1074/jbc.C400260200
110. Demuro A, Mina E, Kayed R, Milton SC, Parker I, Glabe CG. Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J Biol Chem (2005) 280:17294-300. doi:10.1074/jbc.M500997200
111. Stockl MT, Zijlstra N, Subramaniam V. Alpha-synuclein oligomers: an amyloid pore? Insights into the mechanisms of alpha-synuclein oligomer-lipid interactions. Mol Neurobiol (2013) 47:613-21. doi:10.1007/s12035-012-8331-4
112. Flach K, Hilbrich I, Schiffmann A, Gartner U, Kruger M, Leonhardt M, et al. Tau oligomers impair artificial membrane integrity and cellular viability. J Biol Chem (2012) 287:43223-33. doi:10.1074/jbc.M112.396176
113. Jones EM, Dubey M, Camp PJ, Vernon BC, Biernat J, Mandelkow E, et al. Interaction of tau protein with model lipid membranes induces tau structural compaction and membrane disruption. Biochemistry (2012) 51:2539-50. doi:10.1021/bi201857v
114. Kunze G, Barre P, Scheidt HA, Thomas L, Eliezer D, Huster D. Binding of the three-repeat domain of tau to phospholipid membranes induces an aggregated-like state of the protein. Biochim Biophys Acta (2012) 1818:2302-13. doi:10.1016/j.bbamem.2012.03.019
115. Mondragon-Rodriguez S, Trillaud-Doppia E, Dudilot A, Bourgeois C, Lauzon M, Leclerc N, et al. Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation. J Biol Chem (2012) 287:32040-53. doi:10.1074/jbc.M112.401240
116. Narayanan S, Bosl B, Walter S, Reif B. Importance of low-oligomeric-weight species for prion propagation in the yeast prion system Sup35/Hsp104. Proc Natl Acad Sci U S A (2003) 100:9286-91. doi:10.1073/pnas.1233535100
117. Lee HJ, Suk JE, Bae EJ, Lee JH, Paik SR, Lee SJ. Assembly-dependent endocytosis and clearance of extracellular alpha-synuclein. Int J Biochem Cell Biol (2008) 40:1835-49. doi:10.1016/j.biocel.2008.01.017
118. Yu C, Nwabuisi-Heath E, Laxton K, Ladu MJ. Endocytic pathways mediating oligomeric Abeta42 neurotoxicity. Mol Neurodegener (2010) 5:1-11. doi:10.1186/1750-1326-5-19
119. Ivanov A. Pharmacological inhibition of endocytic pathways: is it specific enough to be useful?. In: Ivanov A editor. Exocytosis and Endocytosis. Totowa: Humana Press (2008). p. 15-33.
120. Wang H-Y, Lee DHS, D'Andrea MR, Peterson PA, Shank RP, Reitz AB. β-amyloid1-42 binds to α7 nicotinic acetylcholine receptor with high affinity: implications for Alzheimer's disease pathology. J Biol Chem (2000) 275:5626-32. doi:10.1074/jbc.275.8.5626
121. Nagele RG, D'Andrea MR, Anderson WJ, Wang HY. Intracellular accumulation of β-amyloid1-42 in neurons is facilitated by the α7 nicotinic acetylcholine receptor in Alzheimer's disease. Neuroscience (2002) 110:199-211. doi:10.1016/S0306-4522(01)00460-2
122. Bu G, Cam J, Zerbinatti C. LRP in amyloid-β production and metabolism. Ann N Y Acad Sci (2006) 1086:35-53.
123. Kurup P, Zhang Y, Xu J, Venkitaramani DV, Haroutunian V, Greengard P, et al. Aβ-mediated NMDA receptor endocytosis in Alzheimer's disease involves ubiquitination of the tyrosine phosphatase STEP61. J Neurosci (2010) 30:5948-57. doi:10.1523/JNEUROSCI.0157-10.2010
124. Kessels HW, Nabavi S, Malinow R. Metabotropic NMDA receptor function is required for β-amyloid-induced synaptic depression. Proc Natl Acad Sci U S A (2013) 110:4033-8. doi:10.1073/pnas.1219605110
125. Larson M, Sherman MA, Amar F, Nuvolone M, Schneider JA, Bennett DA, et al. The complex PrPc-Fyn couples human oligomeric Aβ with pathological tau changes in Alzheimer's disease. J Neurosci (2012) 32:16857-71. doi:10.1523/JNEUROSCI.1858-12.2012
126. Klein C, Krämer E-M, Cardine A-M, Schraven B, Brandt R, Trotter J. Process outgrowth of oligodendrocytes is promoted by interaction of Fyn kinase with the cytoskeletal protein tau. J Neurosci (2002) 22:698-707.
127. Bhaskar K, Yen S-H, Lee G. Disease-related modifications in tau affect the interaction between fyn and tau. J Biol Chem (2005) 280:35119-25. doi:10.1074/jbc.M505895200
128. Peters PJ, Mironov A, Peretz D, Van Donselaar E, Leclerc E, Erpel S, et al. Trafficking of prion proteins through a caveolae-mediated endosomal pathway. J Cell Biol (2003) 162:703-17. doi:10.1083/jcb.200304140
129. Simón D, García-García E, Gómez-Ramos A, Falcón-Pérez JM, Díaz-Hernández M, Hernández F, et al. Tau overexpression results in its secretion via membrane vesicles. Neurdegener Dis (2012) 10:73-5. doi:10.1159/000334915
130. Karch CM, Jeng AT, Goate AM. Extracellular tau levels are influenced by variability in tau that is associated with tauopathies. J Biol Chem (2012) 287:42751-62. doi:10.1074/jbc.M112.380642
131. Fackler OT, Grosse R. Cell motility through plasma membrane blebbing. J Cell Biol (2008) 181:879-84. doi:10.1083/jcb.200802081
132. Fevrier B, Vilette D, Archer F, Loew D, Faigle W, Vidal M, et al. Cells release prions in association with exosomes. Proc Natl Acad Sci U S A (2004) 101:9683-8. doi:10.1073/pnas.0308413101
133. Emmanouilidou E, Melachroinou K, Roumeliotis T, Garbis SD, Ntzouni M, Margaritis LH, et al. Cell-produced α-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J Neurosci (2010) 30:6838-51. doi:10.1523/JNEUROSCI.5699-09.2010
134. Simón D, García-García E, Royo F, Falcón-Pérez JM, Avila J. Proteostasis of tau. Tau overexpression results in its secretion via membrane vesicles. FEBS Lett (2012) 586:47-54. doi:10.1016/j.febslet.2011.11.022
135. Saman S, Kim W, Raya M, Visnick Y, Miro S, Jackson B, et al. Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease. J Biol Chem (2012) 287:3842-9. doi:10.1074/jbc.M111.277061
136. Chai X, Dage JL, Citron M. Constitutive secretion of tau protein by an unconventional mechanism. Neurobiol Dis (2012) 48:356-66. doi:10.1016/j.nbd.2012.05.021
137. Gousset K, Schiff E, Langevin C, Marijanovic Z, Caputo A, Browman DT, et al. Prions hijack tunnelling nanotubes for intercellular spread. Nat Cell Biol (2009) 11:328-36. doi:10.1038/ncb1841
138. Castillo-Carranza DL, Lasagna-Reeves CA, Kayed R. Tau aggregates as immunotherapeutic targets. Front Biosci (Schol Ed) (2013) 5:426-38.